Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β- <scp>d</scp> -Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis
Vidmantas Petraitis, Rūta Petraitienė, Aspasia Katragkou, Bo Bo Win Maung, Ethan Naing, Povilas Kavaliauskas, Stephen Barat, Katyna Borroto–Esoda, Nkechi Azie, David Angulo, Thomas J. Walsh
Abstract
< 0.05). Ibrexafungerp and isavuconazole combination demonstrated prolonged survival, decreased pulmonary injury, reduced residual fungal burden, and lower GMI and (1→3)-β-d-glucan levels in comparison to those of single therapy for treatment of IPA. These findings provide an experimental foundation for clinical evaluation of the combination of ibrexafungerp and an antimold triazole for treatment of IPA.
Topics & Concepts
Pulmonary aspergillosisPharmacologyAspergillosisIn vivoCombination therapyGlucanIn vitroMicrobiologyBiologyChemistryBiochemistryImmunologyBiotechnologyAntifungal resistance and susceptibilityFungal Infections and StudiesPeptidase Inhibition and Analysis